INT19829

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 32
Total Number 32
Disease Relevance 12.78
Pain Relevance 8.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Tbxa2r) plasma membrane (Tbxa2r) signal transducer activity (Tbxa2r)
Anatomy Link Frequency
platelet 34
coronary artery 2
endothelial cells 2
liver 2
sympathetic 2
Tbxa2r (Mus musculus)
Pain Link Frequency Relevance Heat
cva 32 99.92 Very High Very High Very High
aspirin 682 99.72 Very High Very High Very High
agonist 62 99.44 Very High Very High Very High
Angina 42 98.64 Very High Very High Very High
cINOD 110 97.94 Very High Very High Very High
Inflammation 146 97.78 Very High Very High Very High
COX2 10 96.96 Very High Very High Very High
antagonist 47 96.88 Very High Very High Very High
COX-2 inhibitor 28 94.96 High High
tetrodotoxin 1 94.36 High High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 73 99.92 Very High Very High Very High
Increased Venous Pressure Under Development 63 99.84 Very High Very High Very High
Lifespan 4 99.28 Very High Very High Very High
Hemorrhage 47 99.08 Very High Very High Very High
Adhesions 26 98.68 Very High Very High Very High
Myocardial Infarction 126 97.88 Very High Very High Very High
INFLAMMATION 182 97.78 Very High Very High Very High
Disorder Of Lipid Metabolism 308 97.60 Very High Very High Very High
Coronary Artery Disease 17 97.08 Very High Very High Very High
Muscular Spasm 4 97.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Since none of the compounds tested produced a sustained inhibition of TXA2 synthesis, the disappointing clinical results with this class of drugs may be due to an incomplete blockade of thromboxane synthase with the dosage regimens used.
Negative_regulation (inhibition) of Gene_expression (synthesis) of TXA2
1) Confidence 0.56 Published 1990 Journal Circulation Section Abstract Doc Link 2136820 Disease Relevance 0.92 Pain Relevance 0.34
The drug was found to inhibit thromboxane A2 (TXA2) production ex vivo as determined by radioimmunoassay (RIA) and to reversibly antagonise the effect of TXA2 on smooth vascular tissue.
Negative_regulation (inhibit) of Gene_expression (production) of TXA2
2) Confidence 0.55 Published 1983 Journal Thromb. Res. Section Abstract Doc Link 6140774 Disease Relevance 0.19 Pain Relevance 0.14
In conclusion, intracoronary administration of a TXA2 synthase inhibitor can relieve ACh-induced coronary spasms by inhibiting TXA2 synthesis in the local coronary circulation.
Negative_regulation (inhibiting) of Gene_expression (synthesis) of TXA2 associated with cva
3) Confidence 0.53 Published 2002 Journal Circ. J. Section Abstract Doc Link 12224820 Disease Relevance 0.80 Pain Relevance 0.34
Therefore, pharmacological interventions aim at an inhibition of the synthesis or action of TXA2 without interference with the desirable effects of prostacyclin.
Negative_regulation (inhibition) of Gene_expression (synthesis) of TXA2
4) Confidence 0.47 Published 1990 Journal Z Kardiol Section Abstract Doc Link 2099038 Disease Relevance 0.19 Pain Relevance 0.27
The increased TxA2 synthesis and the inappropriate increase of peripheral vascular response to sympathetic stimulation revert back to normal in the inactive phase.
Negative_regulation (revert) of Gene_expression (synthesis) of TxA2 in sympathetic
5) Confidence 0.43 Published 1986 Journal Circulation Section Abstract Doc Link 3948351 Disease Relevance 0.66 Pain Relevance 0.43
The use of non-steroidal anti-inflammatory agents in these conditions remains controversial; their possible beneficial effects are believed to be due to inhibition of TXA2 synthesis whereas their failure to be effective may be a consequence of concomitant inhibition of PGI2 production.
Negative_regulation (inhibition) of Gene_expression (synthesis) of TXA2 associated with inflammation
6) Confidence 0.40 Published 1985 Journal Can J Cardiol Section Abstract Doc Link 3850765 Disease Relevance 0.74 Pain Relevance 0.18
The drug was found to inhibit thromboxane A2 (TXA2) production ex vivo as determined by radioimmunoassay (RIA) and to reversibly antagonise the effect of TXA2 on smooth vascular tissue.
Negative_regulation (inhibit) of Gene_expression (production) of thromboxane A2
7) Confidence 0.40 Published 1983 Journal Thromb. Res. Section Abstract Doc Link 6140774 Disease Relevance 0.19 Pain Relevance 0.14
Aspirin irreversibly inhibits TXA2 and PGH2 synthesis in platelets, but also reduces the formation of the platelet-inhibiting PGD2 and prostacyclin--even under a low-dose regimen. 2.
Negative_regulation (inhibits) of Gene_expression (synthesis) of TXA2 in platelet associated with aspirin
8) Confidence 0.39 Published 1990 Journal Z Kardiol Section Abstract Doc Link 2099038 Disease Relevance 0.17 Pain Relevance 0.37
It was suggested that the EPA-containing fish diet might affect platelet aggregation favourably, which followed from the evidence for decreased pathogenic TxA2 generation in the aggregated platelets from FA patients and a lower risk of vascular spasms.
Negative_regulation (decreased) of Gene_expression (generation) of TxA2 in platelets associated with angina and muscular spasm
9) Confidence 0.37 Published 1990 Journal Kardiologiia Section Abstract Doc Link 2290264 Disease Relevance 0.68 Pain Relevance 0.43
Aspirin inhibits platelet activation through the permanent inactivation of the cyclooxygenase (COX) activity of prostaglandin H synthase-1 (referred to as COX-1), and consequently inhibits the biosynthesis of thromboxane A2 (TXA2), a platelet agonist.
Negative_regulation (inhibits) of Gene_expression (biosynthesis) of TXA2 in platelet associated with aspirin and agonist
10) Confidence 0.36 Published 2008 Journal Brain Nerve Section Abstract Doc Link 19069170 Disease Relevance 0.09 Pain Relevance 0.32
These data were confirmed by the in vivo study, which showed a consistent reduction of platelet aggregation and TxA2 production in platelets from eight healthy volunteers taking picotamide 1200 mg/die (Violi et al 1988).
Negative_regulation (reduction) of Gene_expression (production) of TxA2 in platelet
11) Confidence 0.35 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0.05 Pain Relevance 0.14
Furthermore the reduction of platelet aggregation was directly related to the inhibition of TxA2 production.
Negative_regulation (inhibition) of Gene_expression (production) of TxA2 in platelet
12) Confidence 0.35 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0.06 Pain Relevance 0.20
Taken together these results demonstrated that picotamide reduced platelet function by inhibiting TxA2 production without affecting cyclo-oxygenase activity.
Negative_regulation (inhibiting) of Gene_expression (production) of TxA2 in platelet
13) Confidence 0.30 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0.06 Pain Relevance 0.18
Nonspecific COX inhibitors decrease production of both, PGI2 and TxA2 (platelet aggregator), thereby avoiding an imbalance between PGI2 and TxA2 levels [56].
Negative_regulation (decrease) of Gene_expression (production) of TxA2 in platelet
14) Confidence 0.29 Published 2006 Journal Mol Pain Section Body Doc Link PMC1563450 Disease Relevance 0.80 Pain Relevance 0.56
Pretreatment of mice with ketoconazole or its addition to liver fragments ex vivo further increased the production of prostaglandin E2 and reduced the production of thromboxane A2.
Negative_regulation (reduced) of Gene_expression (production) of thromboxane A2 in liver
15) Confidence 0.28 Published 1995 Journal Eur J Gastroenterol Hepatol Section Body Doc Link 7496865 Disease Relevance 0.06 Pain Relevance 0
Aspirin inhibits platelet activation through the permanent inactivation of the cyclooxygenase (COX) activity of prostaglandin H synthase-1 (referred to as COX-1), and consequently inhibits the biosynthesis of thromboxane A2 (TXA2), a platelet agonist.
Negative_regulation (inhibits) of Gene_expression (biosynthesis) of thromboxane A2 in platelet associated with aspirin and agonist
16) Confidence 0.26 Published 2008 Journal Brain Nerve Section Abstract Doc Link 19069170 Disease Relevance 0.09 Pain Relevance 0.32
Moreover Gresele et al (1989) showed that picotamide, apart from reducing the synthesis of TxA2, enhanced the formation of PGE2 in platelets and favored the formation of PGI2 by aspirinated endothelial cells.
Negative_regulation (reducing) of Gene_expression (synthesis) of TxA2 in endothelial cells
17) Confidence 0.26 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0 Pain Relevance 0.10
Inhibitors of TXA2 synthesis (dazoxiben) and of 5-lipoxygenase (nordihydroguaiaretic acid and AA 861) and antagonists of TXA2 (ICI 159995) and peptidoleukotrienes (L 649923 and LY 171883, but not FPL 55712) produced a significant inhibition of the PAF-induced response at concentrations which did not reduce the ACh-induced response.
Negative_regulation (Inhibitors) of Gene_expression (synthesis) of TXA2 associated with antagonist
18) Confidence 0.22 Published 1988 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 3149718 Disease Relevance 0 Pain Relevance 0.32
Reduction in platelet TXA2 generation may be an important mechanism of action of propranolol in patients with coronary artery disease.
Negative_regulation (Reduction) of Gene_expression (generation) of TXA2 in coronary artery associated with coronary artery disease
19) Confidence 0.22 Published 1982 Journal Circulation Section Abstract Doc Link 6216027 Disease Relevance 0.23 Pain Relevance 0
Among these drugs picotamide attracted the attention of researchers for its ability to inhibit both TxA2 platelet synthase and platelet TxA2 receptors and, in turn, platelet aggregation.
Negative_regulation (inhibit) of Gene_expression (synthase) of TxA2 in platelet
20) Confidence 0.22 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0.08 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox